MRNA · 8-K · 20260901PR378505

Senior Notes Issuance

Moderna, Inc. · 2026-09-01 · Importance 64 · Surprise 42

Moderna announced a proposed private placement of $2.0 billion aggregate principal amount of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $300 million. The notes are general senior unsecured obligations, will bear no regular interest, and will not accrete principal; conversion may be settled in cash, common shares, or a combination at Moderna’s election. Moderna expects to use net proceeds to pay for capped call transactions and for general corporate purposes, including potential investment in oncology growth and debt repayment.

Key facts